IB Net Payout Yields Model

Invest like me - only at Covestor.com

C3.ai: Trough Quarter

By -

Update - Apr. 4, 2023

The short attack is here with Kerrisdale Capital attacking the accounting of C3.ai right after the stock soars into the quarter end. The stock already wasn't as appealing back above $30. The accounting questions appear a stretch, but the company has regularly replaced the CFO in the last 4 years. 

  • C3.ai (NYSE:AI) fell 12% after Kerrisdale Capital, which released a short report on the company last month, wrote a letter to the company's auditor outlining its concerns.
  • Kerrisdale, run by Sahm Adrangi, sent a letter to Deloitte & Touche, highlighting its concerns with alleged accounting

Finviz Chart


Update - Apr. 2, 2023

C3.ai had a huge rally to end March likely due to fund managers piling into the stock to report a position at quarter end. The move appears silly but the stock is officially in breakout mode above $30 here. Even SoundHound Ai (SOUN) rallied 40% on Friday.  

  • C3.ai (NYSE:AI) shares surged by more than 21% Friday as investors poured into the artificial intelligence stock on the last day of the first quarter of the year.
  • More than 61M shares of C3.ai (

 Finviz Chart

Original article posted on March 3. 

  • C3.ai, Inc. reported a solid earnings beat, though revenues dipped 5% from last year.
  • The enterprise AI software company made great progress in shifting to the consumption-based pricing model, with strong growth in customers and pilot programs.
  • The stock is still relatively cheap at a forward EV/S multiple below 6x, but investors shouldn't chase C3.ai higher on hype.
C3.ai, Inc. (NYSE:AI) just reported a quarter where revenues fell YoY, yet the stock is soaring. The enterprise AI software company has jumped with all of the generative AI chat hype, but C3.ai reported a trough revenue quarter, likely sending

Read the full article on Seeking Alpha. 

Disclosure: No position mentioned. Please review the disclaimer page for more details. 

Comments

Post a Comment

Popular posts from this blog

Occidental: Still Producing Too Much Oil

By -
Image
Though oil continues plunging, the oil giants continue producing more. For Q4, Occidental Petroleum (OXY) had roughly flat production. The worst part is that OXY plans to grow production by 2% to 4% in 2016. The stock has held up somewhat strong, but the inability to turn off the spigot remains troubling. Disclosure: No positions mentioned. Please review the disclaimer page for more details. 
Read more

ChargePoint: Low Quality Beat

By -
Image
  ChargePoint beat FQ2'22 revenue estimates, but the losses are mounting. The company guided up FY22 numbers partly due to acquisitions. The stock still trades at an estimated 21x FY23 number leaving limited upside for the stock and reinforcing why venture funds sold 13.8 million shares. Looking for a portfolio of ideas like this one? Members of Out Fox The Street get exclusive access to our model portfolio.  Learn More » After  solid FQ2'22 earnings ,  ChargePoint Holdings  ( CHPT ) has seen a nice bump in the stock. Now investors have to confront the valuation divide and deal with the past insider sales likely leading to future sales on any stock rallies. My  investment thesis  remains very Bearish on the EV charging station stock on any rallies into the mid-$20s. Read the full article on Seeking Alpha.  Disclosure: No position mentioned. Please review the disclaimer page for more details.  Update - Sept. 8 Be cautious when analysts struggle to make the bullish case on expen
Read more

Aurora Cannabis: Deal Or No Deal

By -
Aurora Cannabis was left out of the major deal making in 2018. The cannabis company updated FQ2 guidance to revenues of $50 to $55 million with a continued focus on pure production growth. The stock is down as the market is becoming less impressed with commodity farming operations due to the prime Oregon example. The stock is below key resistance at $5.40 as medical cannabis patient totals failed to impress. As the end of 2018 came and went,   Aurora Cannabis   ( ACB ) was a notable absentee from the deal making in the cannabis market. Just about all of the other major Canadian cannabis players got large investments or signed up powerful partnerships, but the related stocks didn't generally maintain rallies following the deals. Based on the early legalization data in Canada and Oregon, the best option for Aurora Cannabis might actually be selling production capacity while the Canadian market remains hot. Read the full article on Seeking Alpha.  Disclosure: No
Read more